By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton
Complete.
,Chapterw01:wDrugwDefinitions,wStandards,wandwInformationwSourceswWi
llihnganz:wClayton’swBasicwPharmacologywforwNurses,w19thwEdition
MULTIPLEwCHOIC
E
1. WhichwnamewidentifieswawdrugwlistedwbywthewUS
wFoodwandwDrugwAdministrationw(FDA)?
a.Brand
b.Nonproprietary
c.Official
d.Trademark
ANS:wC
Thewofficialwnamewiswthew namewunderwwhichwawdru
gwiswlistedwbywthewFDA.wThewbrandwname,worwtrade
mark,wiswthewnamewgivenwtowawdrugwbywitswmanufac
turer.wThewnonproprietary,worwgeneric,wnamewiswprovi
dedwbywthewUnitedwStateswAdoptedwNameswCouncil.
DIF: CognitivewLevel:wKnowledge REF:w p.w9
OBJ:w1NAT:wNCLEXwClientwNeedswCategory:wSafe,wEffect
ivewCarewEnvironmentwTOP:w NursingwProcesswStep:wAssessment
CON:
wPatientwEducation
2. Whichwsourcewcontainswinformationwspecificwtownutritionalwsupplements?
a. USPwDictionarywofwUSANw&wInternationalwDrugwNames
b. NaturalwMedicineswComprehensivewDatabase
c. UnitedwStateswPharmacopoeia/NationalwFormularyw(USPwNF)
d. DrugwInteractionwFacts
ANS:wC
UnitedwStateswPharmacopoeia/NationalwFormularywcontainswinformationwspecificwtown
utritionalwsupplements.wUSPwDictionarywofwUSANw&wInternationalwDrugwNameswisw
awcompilationwofwdrugwnames,wpronunciationwguide,wandwpossiblewfuturewFDAwappr
ovedwdrugs;witwdoeswnotwincludewnutritionalwsupplements.wNaturalwMedicineswComp
rehensivewDatabasewcontains
evidence-
basedwinformationwonwherbalwmedicineswandwherbalwcombinationwproducts;witwdoesw
notwincludewinformationwspecificwtownutritionalwsupplements.wDrugwInteractionwFacts
wcontainswcomprehensivewinformationwonwdrugwinteractionwfacts;witwdoeswnotwinclud
ewnutritionalwsupplements.
DIF: CognitivewLevel:wKnowledge REF:w p.w4
OBJ:w3wNAT:w NCLEXwClientwNeedswCategory:wPhysiologi
calwIntegrity
TOP:w NursingwProcesswStep:wAssessment CON:w Nutritionw|wPatientwEducation
3. Whichwdrugwreferencewcontainswdrugwmonographswthatwdescribewallwdrugswinwawtherapeutic
wclass?
a. DrugwFactswandwComparisons
,TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19th 3
wEdition
b. DrugwInteractionwFacts
c. HandbookwonwInjectablewDrugs
d. Martindale—ThewCompletewDrugwReference
ANS:wA
DrugwFactswandwComparisonswcontainswdrugwmonographswthatwdescribewallw
drugswinwawtherapeuticwclass.wMonographswarewformattedwaswtableswtowallow
wcomparisonwofwsimilarwproducts,wbrandwnames,wmanufacturers,wcostwindices,
wandwavailablewdosagewformswOnlinewversionwiswavailable.
DIF: CognitivewLevel:wKnowledge REF:w p.w4wTablew1.2
OBJ:www3 NAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwIntegrity
TOP:w NursingwProcesswStep:wAssessment CON:w Safetyw|wPatientwEducationw|wClinicalwJudgment
4. Whichwdrugwreferencewcontainswmonographswaboutwvirtuallyweverywsingle-
entitywdrugwavailablewinwthewUnitedwStateswandwdescribeswtherapeuticwuseswofwdru
gs,wincludingwapprovedwandwunapprovedwuses?
a. Martindale:wThewCompletewDrugwReference
b. AHFSwDrugwInformation
c. DrugwReference
d. DrugwFactswandwComparisons
ANS:wB
AHFSwDrugwInformationwcontainswmonographswaboutwvirtuallyweverywsingle-
entitywdrugwavailablewinwthewUnitedwStateswandwdescribeswtherapeuticwuseswofwdrugs
,wincludingwapprovedwandwunapprovedwuses.
DIF: CognitivewLevel:wKnowledge REF:w p.w4wTablew1.2
OBJ:www3 NAT:w NCLEXwClientwNeedswCategory:wPhysiologicalwIntegrity
TOP:w NursingwProcesswStep:wPlanning CON:w Safetyw|wPatientwEducationw|wClinicalwJudgment
5. Whichwonlinewdrugwreferencewmakeswavailablewtowhealthcarewproviderswandwthe
wpublicwawstandard,wcomprehensive,wup-to-
datewlookwupwandwdownloadablewresourcewaboutwmedicines?
a. AmericanwDrugwIndex
b. AmericanwHospitalwFormulary
c. DailyMed
d. DrugwReference
ANS:wC
DailyMedwmakeswavailablewtowhealthcarewproviderswandwthewpublicwawstandard,wco
mprehensive,wup-to-
datewlookwupwandwdownloadablewresourcewaboutwmedicines.wThewAmericanwDrugwI
ndexwiswnotwappropriatewforwpatientwuse.wThewAmericanwHospitalwFormularywiswno
twappropriatewforwpatientwuse.wThewdrugwreferencewiswnotwappropriatewforwpatient
wuse.
DIF: CognitivewLevel:wKnowledge REF:w p.w3w|wp.w4
OBJ:w3wNAT:w NCLEXwClientwNeedswCategory:wPhysiologi
calwIntegrity
TOP:w NursingwProcesswStep:wImplementation
CON:w Safetyw|wPatientwEducationw|wClinicalwJudgment
6. WhichwlegislationwauthorizeswthewFDAwtowdeterminewthewsafetywofwawdrugwbeforewitswmark
eting?
a. FederalwFood,wDrug,wandwCosmeticwActw(1938)
b. DurhamwHumphreywAmendmentw(1952)
, TestwBankwForwClayton’swBasicwPharmacologywforwNursesw19th 4
wEdition
c. ControlledwSubstanceswActw(1970)
d. KefauverwHarriswDrugwAmendmentw(1962)
ANS:wA
ThewFederalwFood,wDrug,wandwCosmeticwActwofw1938wauthorizedwthewFDAwtowdet
erminewthewsafetywofwallwdrugswbeforewmarketing.wLaterwamendmentswandwactswhel
pedwtightenwFDAwcontrolwandwensurewdrugwsafety.wThewDurhamwHumphreywAmen
dmentwdefineswthewkindswofwdrugswthatwcannotwbewusedwsafelywwithoutwmedicalws
upervisionwandwrestrictswtheirwsalewtowprescriptionwbywawlicensedwpractitioner.wThew
ControlledwSubstanceswActwaddresseswonlywcontrolledwsubstanceswandwtheirwcategoriza
tion.wThewKefauverwHarriswDrugwAmendmentwensureswdrugwefficacywandwgreaterwdr
ugwsafety.wDrugwmanufacturerswarewrequiredwtowprovewtowthewFDAwtheweffectivene
sswofwtheirwproductswbeforewmarketingwthem.
DIF: CognitivewLevel:wKnowledge REF:wp.w5wTablewl.3
OBJ:w 5
NAT:wNCLEXwClientwNeedswCategory:wPhysiologicalwI
ntegritywTOP:wNursingwProcesswStep:wAssessment
CON:w Safetyw|wPatientwEducationw|wEvidencew|wHealthwCarewLaw
7. Whichwclassificationwdoeswmeperidinew(Demerol)wfallwunder?
a. I
b. II
c. III
d. IV
ANS:wB
Meperidinew(Demerol)wiswawSchedulewIIwdrug;witwhaswawhighwpotentialwforwabuse
wandwmaywleadwtowseverewpsychologicalwandwphysicalwdependence.wSchedulewIwdru
gswhavewhighwpotentialwforwabusewandwnowrecognizedwmedicalwuse.wSchedulewIIIwd
rugswhavewsomewpotentialwforwabuse.wUsewmaywleadwtowlowwtowmoderatewphysical
wdependenceworwhighwpsychologicalwdependence.wSchedulewIVwdrugswhavewlowwpot
entialwforwabuse.wUsewmaywleadwtowlimitedwphysicalworwpsychologicalwdependence.
DIF: CognitivewLevel:wKnowledge REF:w p.w10
OBJ:w2wNAT:wNCLEXwClientwNeedswCategory:wSafe,wEffe
ctivewCarewEnvironment
TOP:w NursingwProcesswStep:wAssessment CON:w PatientwEducationw|wAddictionw|wPain
8. WhichwactionwwouldwthewFDAwtakewtowexpeditewdrugwdevelopmentwandwapprovalwf
orwanwoutbreakwofwsmallpox?
a. Listwsmallpoxwaswawhealthworphanwdisease.
b. Omitwthewpreclinicalwresearchwphase.
c. Extendwthewclinicalwresearchwphase.
d. Fastwtrackwthewinvestigationalwdrug.
ANS:wD
OncewthewInvestigationalwNewwDrugwApplicationwhaswbeenwapproved,wthewdrugwcan
wreceivewhighestwprioritywwithinwthewagency,wwhichwiswcalledwfastwtracking.wAwsm
allpoxwoutbreakwwouldwbecomewawprioritywconcernwinwthewworld.wOrphanwdiseases
warewnotwresearchedwinwawprioritywmanner.wPreclinicalwresearchwiswnotwomitted.wE
xtendingwanywphasewofwthewresearchwwouldwmeanwawlongerwtimewtowdevelopwawvac
cine.wThewFDAwmustwensurewthatwallwphaseswofwthewpreclinicalwandwclinicalwresearc
hwphasewhavewbeenwcompletedwinwawsafewmanner.
DIF: CognitivewLevel:wKnowledge REF:wwwp.w7 OBJ:w5